Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Q1 revenue up 14% to $1,141 million; EPS $3.47; 2026 outlook raised

Positive Impact 4 of 5 earnings Written later

IDEXX reported first-quarter 2026 revenue of $1,141 million, up 14% as reported and 11% organic, and EPS of $3.47, up 17% as reported. The company raised its 2026 revenue guidance to $4,675 million to $4,760 million and its EPS outlook to $14.45 to $14.90, and said CEO Jay Mazelsky is transitioning from the CEO role.

Key points

  • Q1 2026 revenue $1,141 million, up 14% as reported and 11% organic; Companion Animal Group revenue up 15% as reported.
  • Q1 EPS $3.47, up 17% as reported and 15% comparable; included a $0.05 loss on an equity investment and a $0.14 currency benefit.
  • 2026 revenue guidance raised to $4,675 million to $4,760 million; EPS outlook raised to $14.45 to $14.90 from $14.29 to $14.80.
  • Mazelsky said he is transitioning from the CEO role; the release says he will work with Mike Erickson on long-term growth.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECMay 5, 2026, 6:31 AM ET
Accession number0001104659-26-055203

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.